Pre-implantation Basiliximab Reduces Incidence of Early Acute Rejection in Pediatric Heart Transplantation

Journal of Heart and Lung Transplantation

Volumn 28, Issue 12, 2009, Pages 1279-1284

  Grundy, Nicholas ^a   Simmonds, Jacob ^a   Dawkins, Helen ^a   Rees, Philip ^a   Aurora, Paul ^a   Burch, Michael ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; CARDIAC GRAFT REJECTION; CARDIOPULMONARY BYPASS; CD25+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PEDIATRIC SURGERY; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THORAX SURGERY; VALIDATION STUDY;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; BIOPSY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GREAT BRITAIN; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE COUNT; MALE; PREOPERATIVE CARE; PROGNOSIS; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 70450223686     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.09.001     Document Type: Article

References (22)

1. Flaman F., Zieroth S., Rao V., et al. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 25 (2006) 1358-1362
2. Tejani A., Ho P.L., Emmett L., et al. Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2 (2002) 142-147
3. Ganschow R., Grabhorn E., Schulz A., et al. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatr Transplant 9 (2005) 741-745
4. Koch A., Daniel V., Dengler T.J., et al. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat). J Heart Lung Transplant 24 (2005) 708-713
5. Waldmann T.A. Immunotherapy: past, present and future. Nat Med 9 (2003) 269-277
6. Mehra M.R., Zucker M.J., Wagoner L., et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24 (2005) 1297-1304
7. Mattei M.F., Redonnet M., Gandjbakhch I., et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 26 (2007) 693-699
8. Carrier M., Leblanc M., Perrault L.P., et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 26 (2007) 258-263
9. Dixon V., Macauley C., Burch M., et al. Unsuspected rejection episodes on routine surveillance endomyocardial biopsy post-heart transplant in paediatric patients. Pediatr Transplant 11 (2007) 286-290
10. Boucek M.M., Aurora P., Edwards L.B., et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation report-2007. J Heart Lung Transplant 26 (2007) 796-807
11. Onrust S.V., and Wiseman L.R. Basiliximab. Drugs 57 (1999) 207-213
12. Baquero A., Pérez J., Rizik N., et al. Basiliximab: a comparative study between the use of the recommended two doses versus a single dose in living donor kidney transplantation. Transplant Proc 38 (2006) 909-0
13. Opelz G., and Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 (2004) 222-230
14. Ford K.A., Cale C.M., Rees P.G., et al. Initial data on basiliximab in critically ill children undergoing heart transplantation. J Heart Lung Transplant 24 (2005) 1284-1288
15. Sheashaa H.A., Bakr M.A., Ismail A.M., et al. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 12 (2008) 376-381
16. Ramirez C.B., Doria C., di Francesco F., et al. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transplant Proc 38 (2006) 3633-3636
17. Ruggenenti P. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 1 (2006) 546-554
18. Smith K.A. The interleukin 2 receptor. Annu Rev Cell Biol 5 (1989) 397-425
19. Goggins W.C., Pascual M.A., Powelson J.A., et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 76 (2003) 798-802
20. Höcker B., Kovarik J.M., Daniel V., et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 86 (2008) 1234-1240
21. Wouters K.M., Lane M.H., and Walker I. Acute hypersensitivity reaction on re-exposure to basiliximab in an infant undergoing heart transplantation. Paediatr Anaesth 18 (2008) 806-807
22. Sasaki H., Chikaraishi T., Furuhata S., et al. Anaphylactic reaction after initial exposure of basiliximab: case reports. Transplant Proc 39 (2007) 3457-3459